Innoviva (INVA) Share-based Compensation Growth (1y) (2011 - 2026)
Innoviva (INVA) Share-based Compensation Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 118.32% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -40.86% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 0.18% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5,886.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Innoviva | 1.57 Bn | 969.11 Mn | 75.83 Mn | -95.30% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -95.30% |
| Dec 31, 2025 | 64.09% |
| Sep 30, 2025 | 1,027.96% |
| Jun 30, 2025 | 816.91% |
| Mar 31, 2025 | 431.44% |
| Dec 31, 2024 | 45.72% |
| Sep 30, 2024 | -85.37% |
| Jun 30, 2024 | 70.00% |
| Mar 31, 2024 | 1,856.52% |
| Dec 31, 2023 | 9.15% |
| Sep 30, 2023 | -56.61% |
| Jun 30, 2023 | 17.65% |
| Mar 31, 2023 | -110.75% |
| Dec 31, 2022 | 261.88% |
| Sep 30, 2022 | 6,415.69% |
| Jun 30, 2022 | 36.00% |
| Mar 31, 2022 | 956.00% |
| Dec 31, 2021 | 438.70% |
| Sep 30, 2021 | 525.00% |
| Jun 30, 2021 | -72.22% |